Revolution jumps after US FDA adds its drug under new fast-track process
RefinitivMeno di 1 minuto di lettura
** Shares of drug developer Revolution Medicines RVMD up 7.7% to $53.51 premarket
** U.S. FDA announced nine products, including RVMD's daraxonrasib for pancreatic cancer, under new fast-track review process
** Selected drugs could get approval within one to two months of filing a complete application; typical review time is 10 to 12 months
** Brokerage Oppenheimer thinks daraxonrasib's first approval could come as early as mid-2026
** Eli Lilly's LLY experimental weight-loss pill, orforglipron, was expected to be included in the list
** Separately, Trump signaled the price of LLY's Danish rival Novo Nordisk's weight-loss drug would be lowered
** LLY shares down 4.2% premarket
** YTD, up to last close, RVMD up 13.6% vs LLY's 6.1% rise
Accedi o crea un account gratuito per leggere queste notizie